---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-22-000107"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T19:06:02.898762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology Q3 2022 net loss $14.1M, cash $323.6M; bylaws amended

## Summary
- Operating expenses $15.8M for Q3 2022, up 9% YoY from $14.6M.
- Net loss $14.1M vs $14.5M in Q3 2021; no revenue (pre-revenue biotech).
- Cash, cash equivalents and investments $323.6M as of Sept 30, 2022.
- Company advanced platform development including commercial instrument readiness.
- Bylaws amended to update stockholder nomination procedures and conform to DGLC.

## SEC filing metadata
- accession: 0001808805-22-000107
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/0001808805-22-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/naut-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-22-000107
- JSON: https://secwatch.observer/filing/0001808805-22-000107.json
- Plain text: https://secwatch.observer/filing/0001808805-22-000107.txt

## Key facts
- Earnings Releases
  Nautilus Biotechnology, Inc. reported third quarter ended September 30, 2022 results: net income $14.1 million.
  - Period: third quarter ended September 30, 2022
  - Net income: $14.1 million
  - Result: reported results
  source text: Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/0001808805-22-000107-index.htm
- Governance Changes
  Nautilus Biotechnology, Inc.: Amended and restated bylaws to revise director nomination procedures, stockholder meeting provisions, remove lock-up provisions, update board and officer provisions, and make conforming ministerial changes (effective 2022-10-27).
  - Change: bylaw amendment
  - Effective: 2022-10-27
  source text: On October 27, 2022, the Company’s board of directors, upon recommendation of the nominating and governance committee, amended and restated the Company’s amended and restated bylaws, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/0001808805-22-000107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.